Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Vomiting 2Nausea 2Sarcoma, Alveolar Soft Part 1Pain 1Neurotoxicity Syndromes 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1Delirium 1Breast Neoplasms 1

Interventions

Taxes 2Paclitaxel 2Oxaliplatin 2Magnesium Sulfate 2Carboplatin 2Calcium Gluconate 2haloperidol decanoate 1glutamic acid diethyl ester 1axicabtagene ciloleucel 1Vitamin E 1Vincristine 1Thalidomide 1Surveys and Questionnaires 1Rituximab 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiosurgery 1Procarbazine 1Peripheral Blood Stem Cell Transplantation 1Pain Management 1Modafinil 1Methotrexate 1Memantine 1Melphalan 1Lorazepam 1Leucovorin 1Lamotrigine 1Ketamine 1Interleukin 1 Receptor Antagonist Protein 1In Situ Hybridization, Fluorescence 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neurotoxicity Syndromes × Lorazepam × Clear all
NCT01949662 2026-02-13

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
93 enrolled 14 charts
Other hematologic neoplasm

Delirium, Hematologic Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡